Absence of immunostaining for growth hormone in a subset of patients with acromegaly

Jason L. Schroeder, Alejandro M. Spiotta, Maria Fleseriu, Richard A. Prayson, Amir H. Hamrahian, Robert J. Weil

Research output: Contribution to journalArticle

Abstract

The presence of growth hormone (GH) immunostaining in patients who lack the biochemical and clinical features of acromegaly has been described. In contrast, there is little information on the absence of GH immunostaining in patients with acromegaly. We describe five patients with acromegaly with no intratumoral immunostaining for GH. We reviewed all patients undergoing surgery for acromegaly. Out of 136 patients treated surgically in a 10 year period, five (3.7 %) were found to have no GH immunostaining on repetitive testing at pathological examination. Their pathology slides were re-examined by an experienced neuropathologist, along with twenty nonfunctional pituitary tumors and ten GH-positive adenomas as negative and positive controls, respectively. All patients had clinical features consistent with acromegaly and elevated baseline insulin-like growth factor-1 (IGF-1) and GH. All patients had no immunostaining for GH on multiple inspections. Of twenty patients with nonfunctional tumors, two had ≤25 % staining for GH in a scattered and non-coherent pattern and the rest were negative. In all ten positive control patients >25 % of the tumor cells stained diffusely for GH. All five patients achieved biochemical remission at 1.4-8 years post-op using a combination of primary surgery alone (n = 1), repeat surgery (n = 1), radiotherapy (n = 3) and/or medical therapy (n = 2). GH immunostaining of an adenoma may not be sufficient to confirm the diagnosis of acromegaly. All patients in our small series achieved remission by multimodality therapies. Further studies are needed to evaluate the significance of our observation and whether this subset of patients follows a distinct long term clinical course.

Original languageEnglish (US)
Pages (from-to)103-108
Number of pages6
JournalPituitary
Volume17
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Acromegaly
Growth Hormone
Adenoma
Pituitary Neoplasms
Somatomedins
Reoperation
Neoplasms
Radiotherapy
Observation

Keywords

  • Growth hormone
  • Immunohistochemistry
  • Insulin-like growth factor 1
  • Intensity-modulated radiotherapy
  • Pituitary adenoma
  • Stereotactic radiosurgery
  • Surgery

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Schroeder, J. L., Spiotta, A. M., Fleseriu, M., Prayson, R. A., Hamrahian, A. H., & Weil, R. J. (2014). Absence of immunostaining for growth hormone in a subset of patients with acromegaly. Pituitary, 17(2), 103-108. https://doi.org/10.1007/s11102-013-0474-4

Absence of immunostaining for growth hormone in a subset of patients with acromegaly. / Schroeder, Jason L.; Spiotta, Alejandro M.; Fleseriu, Maria; Prayson, Richard A.; Hamrahian, Amir H.; Weil, Robert J.

In: Pituitary, Vol. 17, No. 2, 2014, p. 103-108.

Research output: Contribution to journalArticle

Schroeder, JL, Spiotta, AM, Fleseriu, M, Prayson, RA, Hamrahian, AH & Weil, RJ 2014, 'Absence of immunostaining for growth hormone in a subset of patients with acromegaly', Pituitary, vol. 17, no. 2, pp. 103-108. https://doi.org/10.1007/s11102-013-0474-4
Schroeder, Jason L. ; Spiotta, Alejandro M. ; Fleseriu, Maria ; Prayson, Richard A. ; Hamrahian, Amir H. ; Weil, Robert J. / Absence of immunostaining for growth hormone in a subset of patients with acromegaly. In: Pituitary. 2014 ; Vol. 17, No. 2. pp. 103-108.
@article{5922b8ca5d0e4e5ea81c67332315e4cd,
title = "Absence of immunostaining for growth hormone in a subset of patients with acromegaly",
abstract = "The presence of growth hormone (GH) immunostaining in patients who lack the biochemical and clinical features of acromegaly has been described. In contrast, there is little information on the absence of GH immunostaining in patients with acromegaly. We describe five patients with acromegaly with no intratumoral immunostaining for GH. We reviewed all patients undergoing surgery for acromegaly. Out of 136 patients treated surgically in a 10 year period, five (3.7 {\%}) were found to have no GH immunostaining on repetitive testing at pathological examination. Their pathology slides were re-examined by an experienced neuropathologist, along with twenty nonfunctional pituitary tumors and ten GH-positive adenomas as negative and positive controls, respectively. All patients had clinical features consistent with acromegaly and elevated baseline insulin-like growth factor-1 (IGF-1) and GH. All patients had no immunostaining for GH on multiple inspections. Of twenty patients with nonfunctional tumors, two had ≤25 {\%} staining for GH in a scattered and non-coherent pattern and the rest were negative. In all ten positive control patients >25 {\%} of the tumor cells stained diffusely for GH. All five patients achieved biochemical remission at 1.4-8 years post-op using a combination of primary surgery alone (n = 1), repeat surgery (n = 1), radiotherapy (n = 3) and/or medical therapy (n = 2). GH immunostaining of an adenoma may not be sufficient to confirm the diagnosis of acromegaly. All patients in our small series achieved remission by multimodality therapies. Further studies are needed to evaluate the significance of our observation and whether this subset of patients follows a distinct long term clinical course.",
keywords = "Growth hormone, Immunohistochemistry, Insulin-like growth factor 1, Intensity-modulated radiotherapy, Pituitary adenoma, Stereotactic radiosurgery, Surgery",
author = "Schroeder, {Jason L.} and Spiotta, {Alejandro M.} and Maria Fleseriu and Prayson, {Richard A.} and Hamrahian, {Amir H.} and Weil, {Robert J.}",
year = "2014",
doi = "10.1007/s11102-013-0474-4",
language = "English (US)",
volume = "17",
pages = "103--108",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Absence of immunostaining for growth hormone in a subset of patients with acromegaly

AU - Schroeder, Jason L.

AU - Spiotta, Alejandro M.

AU - Fleseriu, Maria

AU - Prayson, Richard A.

AU - Hamrahian, Amir H.

AU - Weil, Robert J.

PY - 2014

Y1 - 2014

N2 - The presence of growth hormone (GH) immunostaining in patients who lack the biochemical and clinical features of acromegaly has been described. In contrast, there is little information on the absence of GH immunostaining in patients with acromegaly. We describe five patients with acromegaly with no intratumoral immunostaining for GH. We reviewed all patients undergoing surgery for acromegaly. Out of 136 patients treated surgically in a 10 year period, five (3.7 %) were found to have no GH immunostaining on repetitive testing at pathological examination. Their pathology slides were re-examined by an experienced neuropathologist, along with twenty nonfunctional pituitary tumors and ten GH-positive adenomas as negative and positive controls, respectively. All patients had clinical features consistent with acromegaly and elevated baseline insulin-like growth factor-1 (IGF-1) and GH. All patients had no immunostaining for GH on multiple inspections. Of twenty patients with nonfunctional tumors, two had ≤25 % staining for GH in a scattered and non-coherent pattern and the rest were negative. In all ten positive control patients >25 % of the tumor cells stained diffusely for GH. All five patients achieved biochemical remission at 1.4-8 years post-op using a combination of primary surgery alone (n = 1), repeat surgery (n = 1), radiotherapy (n = 3) and/or medical therapy (n = 2). GH immunostaining of an adenoma may not be sufficient to confirm the diagnosis of acromegaly. All patients in our small series achieved remission by multimodality therapies. Further studies are needed to evaluate the significance of our observation and whether this subset of patients follows a distinct long term clinical course.

AB - The presence of growth hormone (GH) immunostaining in patients who lack the biochemical and clinical features of acromegaly has been described. In contrast, there is little information on the absence of GH immunostaining in patients with acromegaly. We describe five patients with acromegaly with no intratumoral immunostaining for GH. We reviewed all patients undergoing surgery for acromegaly. Out of 136 patients treated surgically in a 10 year period, five (3.7 %) were found to have no GH immunostaining on repetitive testing at pathological examination. Their pathology slides were re-examined by an experienced neuropathologist, along with twenty nonfunctional pituitary tumors and ten GH-positive adenomas as negative and positive controls, respectively. All patients had clinical features consistent with acromegaly and elevated baseline insulin-like growth factor-1 (IGF-1) and GH. All patients had no immunostaining for GH on multiple inspections. Of twenty patients with nonfunctional tumors, two had ≤25 % staining for GH in a scattered and non-coherent pattern and the rest were negative. In all ten positive control patients >25 % of the tumor cells stained diffusely for GH. All five patients achieved biochemical remission at 1.4-8 years post-op using a combination of primary surgery alone (n = 1), repeat surgery (n = 1), radiotherapy (n = 3) and/or medical therapy (n = 2). GH immunostaining of an adenoma may not be sufficient to confirm the diagnosis of acromegaly. All patients in our small series achieved remission by multimodality therapies. Further studies are needed to evaluate the significance of our observation and whether this subset of patients follows a distinct long term clinical course.

KW - Growth hormone

KW - Immunohistochemistry

KW - Insulin-like growth factor 1

KW - Intensity-modulated radiotherapy

KW - Pituitary adenoma

KW - Stereotactic radiosurgery

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84898770077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898770077&partnerID=8YFLogxK

U2 - 10.1007/s11102-013-0474-4

DO - 10.1007/s11102-013-0474-4

M3 - Article

C2 - 23475513

AN - SCOPUS:84898770077

VL - 17

SP - 103

EP - 108

JO - Pituitary

JF - Pituitary

SN - 1386-341X

IS - 2

ER -